Biotechnology
Phenomenex Celebrates 40-Years of Keeping Scientists Happy & What's to Come
TORRANCE, Calif., Feb. 3, 2022 /PRNewswire/ -- Phenomenex, a global life sciences company that offers analytical chemistry solutions for separation and purification, proudly marks its40th anniversary in 2022 with a new mission statement and several exciting strategic initiatives that will deliver...
2022-02-03 06:49
2426
Avidien Technologies Receives $4M Investment from BroadOak Capital Partners
BOSTON, Feb. 2, 2022 /PRNewswire/ -- Avidien announced today a new financing round of$4M from BroadOak Capital Partners. The investment will help Avidien expand its product roadmap, scale commercial production, and better serve research and pharmaceutical clients. Avidien CEO and Founder Rich Co...
2022-02-02 18:49
2109
CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma
LUXEMBOURG, Feb. 2, 2022 /PRNewswire/ -- CordenPharma, a leading, full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities...
2022-02-02 11:00
2485
World's most trusted source for chemistry information, CAS, launches major biology expansion
CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities COLUMBUS, Ohio, Feb. 2, 2022 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific information solutions, announce...
2022-02-02 10:42
2471
New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good
TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...
2022-02-01 21:00
1918
AMR Action Fund Appoints Scientific Advisory Board
Members will play a vital role in evaluating potential investments into clinical-stage companies developing urgently needed antibiotics BOSTON, Feb. 1, 2022 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in the development of new antibiotics, today ...
2022-02-01 19:00
2455
Cytiva fuels biotech development in Australia and New Zealand
* VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. * Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, F...
2022-02-01 07:00
2779
DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA
LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ --
Debiopharm (www.debiopharm.com
2022-02-01 06:00
2988
Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)
SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-r...
2022-02-01 05:30
2187
Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement
* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...
2022-01-31 19:00
1537
Pfizer and Alex Therapeutics announce a Strategic Commercial Partnership to provide evidence-based Digital Therapeutics to patients, starting in Germany
STOCKHOLM, Jan. 31, 2022 /PRNewswire/ -- The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined forces to provide evidence based, clinically validated and personalized digital therapies to patients. Together, the compa...
2022-01-31 18:00
2113
AKESO'S LIGUFALIMAB AND IVONESCIMAB OBTAINED APPROVAL TO INITIATE A PHASE II TRIAL
HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and Ivonescimab (PD-1/VEGF bi-specific antibody, research and devel...
2022-01-31 10:14
2018
AKESO DOSES FIRST PATIENT IN THE PHASE III TRIAL OF IVONESCIMAB COMBINED WITH CHEMOTHERAPY IN EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the first patient was dosed in a Phase III registrational clinical trial of the Company's novel immuno-oncology drug, Ivonescimab (PD-1/VEGF bi-specific antibody, AK112), combined with chemotherapy versus placebo combin...
2022-01-31 09:51
1882
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital
SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed aUS$40 million Series A financing to advance the preclinical and clinical develop...
2022-01-29 11:37
6347
Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 29, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two compan...
2022-01-29 05:28
3837
CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA
NANJING, China, Jan. 28, 2022 /PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co.,Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for t...
2022-01-28 22:00
2620
Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast
* Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will ...
2022-01-28 22:00
5903
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qian...
2022-01-28 21:00
2297
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease
MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple S...
2022-01-28 20:08
1865
Ready to Enter the Middle East Market, Vazyme Showcases Its COVID-19 Testing Solutions at Medlab Middle East 2022
DUBAI, UAE, Jan. 28, 2022 /PRNewswire/ -- Leading China-based biotech company Vazyme (688105.SH) participated in the 2022 edition of Medlab Middle East in the Dubai World Trade Centre (DWTC) fromJanuary 24th to 27th, a leading laboratory and flagship exhibition and conference that brings together...
2022-01-28 13:00
3419
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 276 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
6968
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4468
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
4365
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
4242